Parkinson Disease
Conditions
Keywords
Mindfulness, Adapted MBSR program, Feasibility, Efficacy
Brief summary
The objective of this study is to determine the feasibility (primary objective) and the effects (secondary objectives) of an Mindfulness Based Stress Reduction (MBSR) program adapted specifically for patients with Parkinson's disease.
Detailed description
In Parkinson's disease (PD) the psychological distress (anxiety and depression), is particularly impacting and often resistant to conventional drug treatment explaining the growing interest of patients in non-drug methods, such as mindfulness meditation. The Mindfulness Based Stress Reduction (MBSR) program has been evaluated in Parkinson's disease, showing main effects on anxiety and depression symptoms. These data remain, however, still fragile, particularly in terms of methodological robustness and number of patients involved and variable size of effects. A clinical trial was recently conducted at the Bordeaux University Hospital with 28 patients with Parkinson's disease . Preliminary results suggest that a program tailored specifically to the expectations and needs of patients with Parkinson's disease could, optimize accessibility, acceptability, and patient compliance for this type of approach while preserving clinical efficacy on anxiety and depression.
Interventions
PROCEDUREMindfulness Based Stress Reduction
Inspired by the standard Mindfulness Based Stress Reductio program, the study MAdaPARK is a 8 week program with weekly sessions of 2h30 and a full day of practice designed from the analysis of the post-program interviews carried out as part of the M-PARK study,as well as the reflections of the working group specially set up for this purpose. Several areas of adaptation have been identified: shorter mediations, a break time during the sessions, more times for exchanges, a more developed practice in movement, and finally, more important work based on self-esteem and self-compassion.
Sponsors
University Hospital, Bordeaux
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
* Patient suffering from Parkinson's disease, * Patient aged over 18 and under 80, * Patient with a Hoehn and Yahr Stage of 1 to 3, * Patient affiliated or beneficiary of the social security system, * Patient having signed a free, informed and written consent
Exclusion criteria
* Patient with severe motor fluctuations (i.e. scoring 4 to at least one of the following items of part IV of the Movement Disorder Society Unified Parkinson Disease Rating Scale: 4.1 and 4.2 for dyskinesias; 4.3, 4.4 and 4.5 for motor fluctuations), * Patient with acute depression not stabilized by treatment or dating from less than 6 months, * Patient with non-stabilized psycho-behavioral disorders (hallucinations, psychoses, impulse control disorders) dating from less than 6 months, * Patient with major cognitive impairment (Montreal Cognitive Assessment ≤24), * Patient who has already participated in a structured mindfulness meditation program * Patient placed under judicial safeguard, guardianship or curator ship, * Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assess MBSR program | Month 4 | The rate of patients who have completed the entire MBSR program "adapted" |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Attendance rate | Month 3 | Number of days of practice and daily meditation time. |
| Program tolerance | month 1 at month 2 | Number of side effects and the difficulties |
| Relevance of the adaptations put in place | month 3 | It will be evaluated from the analysis of feelings and impressions of patients . These different elements will be obtained from the analysis of the semi-directed interviews (qualitative analysis). |
| Beck Depression Inventory | Day 0 and month 3 | Assessment depressive symptoms, minimum value 0 and maximum value 36 |
| Parkinson Anxiety Scale (PAS) | Day 0 and month 3 | Assessment anxiety symptoms,minimum value 0 and maximum value 48 |
| Parkinson's Disease Sleep Scale | Day 0 and month 3 | Assessment sleep, minimum value 0 and maximum value 60 |
| Parkinson Disease Questionnaire | Day 0 and month 3 | Assessment quality of life, minimum value 0 and maximum value 156 |
| Movement Disorder Society Unified Parkinson Disease Rating Scale | Day 0 and month 3 | Assessment motor and non-motor symptoms of Parkinson Disease |
| King's college Parkinson's disease Pain Scale | Day 0 and month 3 | Assessment pain, minimum value 0 and maximum value 168 |
| Number of Anti-parkinsonian and psychotropic treatments | Day 0 and month 3 | — |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORFrançois TISON, Pr
Université Hospital, Bordeaux
Outcome results
None listed